Recommended Initial Dosing for Truxima (Rituximab) in Non-Hodgkin's Lymphoma

Dosing Recommendations

The National Comprehensive Cancer Network recommends an initial dosing for Truxima (rituximab) in patients with non-Hodgkin's lymphoma of 375 mg/m² administered intravenously once weekly for 4 weeks 1, 2, 3
For patients with indolent non-Hodgkin's lymphoma, the National Comprehensive Cancer Network recommends rituximab 375 mg/m² IV weekly for 4 doses, either as monotherapy or in combination regimens 1, 2
For elderly or infirm patients with indolent non-Hodgkin's lymphoma, the National Comprehensive Cancer Network recommends rituximab 375 mg/m² IV weekly for 4 doses as a preferred option for those who cannot tolerate combination therapy 1, 3

The National Comprehensive Cancer Network recommends bendamustine + rituximab as a category 1 recommendation for patients with indolent non-Hodgkin's lymphoma 1
The National Comprehensive Cancer Network recommends RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) as a category 1 recommendation for patients with aggressive non-Hodgkin's lymphoma 2
The National Comprehensive Cancer Network recommends RCVP (rituximab, cyclophosphamide, vincristine, prednisone) as a category 1 recommendation for patients with indolent non-Hodgkin's lymphoma 2

For patients initially presenting with high tumor burden, the National Comprehensive Cancer Network recommends rituximab maintenance 375 mg/m² one dose every 8 weeks for 12 doses (category 1) 3
For patients initially treated with single-agent rituximab, the National Comprehensive Cancer Network recommends consolidation with rituximab 375 mg/m² one dose every 8 weeks for 4 doses 3

The National Comprehensive Cancer Network recommends monitoring for viral reactivation, particularly hepatitis B virus (HBV) 6
The National Comprehensive Cancer Network recommends monitoring for progressive multifocal leukoencephalopathy (PML), a rare but serious complication 6
The National Comprehensive Cancer Network recommends considering prophylaxis for tumor lysis syndrome in high-risk patients 3

For elderly or infirm patients who cannot tolerate combination therapy, the National Comprehensive Cancer Network recommends single-agent rituximab at 375 mg/m² weekly for 4 doses 2